UNION OF THRACE UNIVERSITIES V. INTERNATIONAL HEALTH SCIENCES CONGRESS 2022, Balıkesir, Turkey, 1 - 02 December 2022, pp.14
Migraine is one of the most common chronic neurovascular diseases worldwide. The most prominent symptoms of the disease are attacks of moderate or severe headache, a chronic neurological disorder. Current studies suggest that the most acute symptoms associated with migraine include photophobia, phonophobia, cutaneous allodynia, and gastrointestinal symptoms such as nausea and vomiting. Although many studies have been conducted on the origin of the disease, the molecular mechanisms underlying migraine are still not fully understood.
The transient receptor potential (TRP) vanilloid-1 (TRPV1) channel, a member of the TRP channel family, is well characterised in the mammalian body, expressed by a subset of peripheral sensory neurons involved in the sensation of pain and several other neuronal and non-neuronal regions. The literature shows that stimulation of TRPV1 causes a burning sensation reflecting the central role of the channel in pain. Pharmacological and genetic studies have confirmed that TRPV1 is a therapeutic target in various preclinical chronic pain models, including cancer, neuropathic, postoperative, and musculoskeletal pain. In addition, in vivo, experimental pain model studies have shown that TRPV1 antagonists effectively reduce pain. Another experimental migraine model study highlighted the TRPV1 channel's role in nociceptive trigeminocervical signalling via the trigeminocervical complex or neurogenic dural vasodilation. In a clinical study, 46 patients diagnosed with migraine (27 episodic and 19 chronic) and 50 healthy individuals were in the control group; It was concluded that TRPV1 1911A>G SNP genotyping can be used as a prognostic factor and clinical biomarker to predict the severity of migraine and to choose a timely prophylactic treatment strategy. In other studies on migraine pain, it has been stated that there is an important relationship between TRPV1 and the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP).
In conclusion, when examining the existing literature data that there is an important relationship between migraine and the TRPV1 channel, it will be important to clarify the role of the TRPV1 channel in this mechanism to understand better the molecular mechanisms related to migraine pain. Thus, we think that the control of cell activation of the TRPV1 channel will provide a therapeutic approach as a pharmacological target in treating migraine.